Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Granisetron-d3
Price:
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang

1224925-64-7

1224925-64-7 structure

Name: Granisetron-d3
Chemical Name: Granisetron-d3
CAS Number: 1224925-64-7
Molecular Formula: C₁₈H₂₁D₃N₄O
Molecular Weight: 315.43
Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
Create Date: 2021-10-30 20:54:44
Modify Date: 2024-01-09 17:20:30
Granisetron-d3 (BRL 43694-d3) is the deuterium labeled Granisetron. Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy[1][2].

Name	Granisetron-d3

Description	Granisetron-d3 (BRL 43694-d3) is the deuterium labeled Granisetron. Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy[1][2].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol. 1989 Jan 10;159(2):113-24. [3]. Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. Int Immunopharmacol. 2010 Sep;10(9):1010-6. [4]. Boccia RV, Gordan LN, Clark G, Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011 Oct;19(10):1609-17.

Molecular Formula	C₁₈H₂₁D₃N₄O
Molecular Weight	315.43

1224925-76-1	1224925-64-7
2124272-02-0	2124272-03-1
127472-42-8	107007-95-4
109889-09-0	107007-99-8
18164-03-9	1219803-43-6
2138349-01-4	1158522-08-7
940364-43-2	134104-43-1
2227695-65-8	131615-57-1
6906-52-1	2138108-04-8
930439-75-1	1018584-77-4